OCUL Fundamental Analysis - OCULAR THERAPEUTIX INC

Name: OCULAR THERAPEUTIX INC (OCUL) Stock
Brand: OCULAR THERAPEUTIX INC
Rating: 5.5 (3 reviews)

Fundamental Rating

Taking everything into account, OCUL scores 4 out of 10 in our fundamental rating. OCUL was compared to 192 industry peers in the Pharmaceuticals industry. OCUL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. OCUL is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

OCUL had negative earnings in the past year.

OCUL had a negative operating cash flow in the past year.

OCUL had negative earnings in each of the past 5 years.

In the past 5 years OCUL always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of OCUL (-48.02%) is comparable to the rest of the industry.

With a Return On Equity value of -70.85%, OCUL perfoms like the industry average, outperforming 47.92% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-48.02%
ROE	-70.85%
ROIC	N/A

ROA(3y)-40.62%

ROA(5y)-36.9%

ROE(3y)-116.88%

ROE(5y)-112.52%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 89.42%, OCUL belongs to the top of the industry, outperforming 92.19% of the companies in the same industry.

OCUL's Gross Margin has improved in the last couple of years.

The Profit Margin and Operating Margin are not available for OCUL so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	89.42%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.47%

GM growth 5Y15.21%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

OCUL does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, OCUL has more shares outstanding

Compared to 5 years ago, OCUL has more shares outstanding

Compared to 1 year ago, OCUL has an improved debt to assets ratio.

2.2 Solvency

OCUL has an Altman-Z score of 6.35. This indicates that OCUL is financially healthy and has little risk of bankruptcy at the moment.

The Altman-Z score of OCUL (6.35) is better than 79.17% of its industry peers.

A Debt/Equity ratio of 0.23 indicates that OCUL is not too dependend on debt financing.

OCUL's Debt to Equity ratio of 0.23 is in line compared to the rest of the industry. OCUL outperforms 42.71% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.23
Debt/FCF	N/A
Altman-Z	6.35

ROIC/WACCN/A

WACC9.25%

2.3 Liquidity

OCUL has a Current Ratio of 10.09. This indicates that OCUL is financially healthy and has no problem in meeting its short term obligations.

OCUL has a Current ratio of 10.09. This is amongst the best in the industry. OCUL outperforms 81.77% of its industry peers.

A Quick Ratio of 10.02 indicates that OCUL has no problem at all paying its short term obligations.

OCUL has a Quick ratio of 10.02. This is amongst the best in the industry. OCUL outperforms 81.77% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	10.09
Quick Ratio	10.02

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 13.51% over the past year.

Looking at the last year, OCUL shows a decrease in Revenue. The Revenue has decreased by -7.25% in the last year.

OCUL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 72.02% yearly.

EPS 1Y (TTM)13.51%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-50%

Revenue 1Y (TTM)-7.25%

Revenue growth 3Y13.55%

Revenue growth 5Y72.02%

Sales Q2Q%-18.14%

3.2 Future

The Earnings Per Share is expected to grow by 20.11% on average over the next years. This is a very strong growth

OCUL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 50.68% yearly.

EPS Next Y-1.48%

EPS Next 2Y2.07%

EPS Next 3Y6%

EPS Next 5Y20.11%

Revenue Next Year-13.73%

Revenue Next 2Y0.79%

Revenue Next 3Y15.87%

Revenue Next 5Y50.68%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

OCUL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OCUL. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y2.07%

EPS Next 3Y6%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

OCUL does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

OCULAR THERAPEUTIX INC

NASDAQ:OCUL (10/29/2025, 8:00:02 PM)

After market: 11.48 0 (0%)

11.48

-0.05 (-0.43%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)08-05 2025-08-05/bmo

Earnings (Next)11-10 2025-11-10/amc

Inst Owners90.09%

Inst Owner Change-0.15%

Ins Owners2.76%

Ins Owner Change-0.16%

Market Cap2.42B

Revenue(TTM)56.66M

Net Income(TTM)-216748000

Analysts85.56

Price Target18.19 (58.45%)

Short Float %6.68%

Short Ratio4.76

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-17.23%

Min EPS beat(2)-26.63%

Max EPS beat(2)-7.83%

EPS beat(4)1

Avg EPS beat(4)-9.12%

Min EPS beat(4)-26.63%

Max EPS beat(4)10.95%

EPS beat(8)2

Avg EPS beat(8)-35.12%

EPS beat(12)4

Avg EPS beat(12)-27.59%

EPS beat(16)7

Avg EPS beat(16)-6.73%

Revenue beat(2)0

Avg Revenue beat(2)-19.06%

Min Revenue beat(2)-37.69%

Max Revenue beat(2)-0.44%

Revenue beat(4)0

Avg Revenue beat(4)-13.14%

Min Revenue beat(4)-37.69%

Max Revenue beat(4)-0.44%

Revenue beat(8)1

Avg Revenue beat(8)-8.42%

Revenue beat(12)3

Avg Revenue beat(12)-7.38%

Revenue beat(16)3

Avg Revenue beat(16)-8.36%

PT rev (1m)1.64%

PT rev (3m)-0.93%

EPS NQ rev (1m)4.21%

EPS NQ rev (3m)-3.25%

EPS NY rev (1m)3.96%

EPS NY rev (3m)-1.94%

Revenue NQ rev (1m)1.04%

Revenue NQ rev (3m)0.46%

Revenue NY rev (1m)0.37%

Revenue NY rev (3m)-0.01%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	42.71
P/FCF	N/A
P/OCF	N/A
P/B	7.91
P/tB	7.91
EV/EBITDA	N/A

EPS(TTM)-1.28

EYN/A

EPS(NY)-1.41

Fwd EYN/A

FCF(TTM)-0.85

FCFYN/A

OCF(TTM)-0.83

OCFYN/A

SpS0.27

BVpS1.45

TBVpS1.45

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-48.02%
ROE	-70.85%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	89.42%
FCFM	N/A

ROA(3y)-40.62%

ROA(5y)-36.9%

ROE(3y)-116.88%

ROE(5y)-112.52%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.47%

GM growth 5Y15.21%

F-Score2

Asset Turnover0.13

Health

		Industry Rank	Sector Rank
Debt/Equity	0.23
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	88.56%
Cap/Sales	6.12%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	10.09
Quick Ratio	10.02
Altman-Z	6.35

F-Score2

WACC9.25%

ROIC/WACCN/A

Cap/Depr(3y)138.13%

Cap/Depr(5y)98.78%

Cap/Sales(3y)6.55%

Cap/Sales(5y)5.44%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)13.51%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-50%

EPS Next Y-1.48%

EPS Next 2Y2.07%

EPS Next 3Y6%

EPS Next 5Y20.11%

Revenue 1Y (TTM)-7.25%

Revenue growth 3Y13.55%

Revenue growth 5Y72.02%

Sales Q2Q%-18.14%

Revenue Next Year-13.73%

Revenue Next 2Y0.79%

Revenue Next 3Y15.87%

Revenue Next 5Y50.68%

EBIT growth 1Y-99.3%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-59.92%

EBIT Next 3Y-8.65%

EBIT Next 5Y23.93%

FCF growth 1Y-128.52%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-150.67%

OCF growth 3YN/A

OCF growth 5YN/A

OCULAR THERAPEUTIX INC / OCUL FAQ

What is the ChartMill fundamental rating of OCULAR THERAPEUTIX INC (OCUL) stock?

ChartMill assigns a fundamental rating of 4 / 10 to OCUL.

What is the valuation status for OCUL stock?

ChartMill assigns a valuation rating of 0 / 10 to OCULAR THERAPEUTIX INC (OCUL). This can be considered as Overvalued.

How profitable is OCULAR THERAPEUTIX INC (OCUL) stock?

OCULAR THERAPEUTIX INC (OCUL) has a profitability rating of 2 / 10.

What is the expected EPS growth for OCULAR THERAPEUTIX INC (OCUL) stock?

The Earnings per Share (EPS) of OCULAR THERAPEUTIX INC (OCUL) is expected to decline by -1.48% in the next year.

OCULAR THERAPEUTIX INC (OCUL) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

OCULAR THERAPEUTIX INC / OCUL FAQ

What is the ChartMill fundamental rating of OCULAR THERAPEUTIX INC (OCUL) stock?

What is the valuation status for OCUL stock?

How profitable is OCULAR THERAPEUTIX INC (OCUL) stock?

What is the expected EPS growth for OCULAR THERAPEUTIX INC (OCUL) stock?